Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lowering hyperuricemia improved endothelial function but failed as an antihypertensive

Publish date:: June 14, 2019

Key clinical point: Reducing hyperuricemia with allopurinol improved endothelial function as measured by flow-mediated dilation.

Major finding: Allopurinol treatment was associated with a 4.2% absolute increase in flow-mediated dilation, a 41% relative increase from baseline.

Study details: SURPHER, a single-center crossover study with 82 participants completing the full protocol.

Disclosures: SURPHER received no commercial funding. Dr. Gaffo has received research funding from Amgen and AstraZeneca.

Citation:

REPORTING FROM EULAR 2019 CONGRESS

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Cardiology

Sac/val heart failure benefit extends to diabetes patients,

Sedentary postmenopausal women have higher heart failure risk,

Experts disagree with USPSTF’s take on pediatric blood pressure screening,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,

Don’t miss cardiovascular risk factors in transgender patients,